Quarterly ResultJul 6, 2026, 04:17 PM
AbbVie Updates Q2, Full-Year 2026 EPS Guidance Due to IPR&D Expense
AI Summary
AbbVie Inc. announced preliminary second-quarter 2026 results are expected to include a $291 million pre-tax acquired IPR&D and milestones expense. This expense will unfavorably impact both GAAP and non-GAAP diluted earnings per share by $0.17. Consequently, the company has updated its Q2 2026 adjusted diluted EPS guidance to $3.57 - $3.61 and its full-year 2026 adjusted diluted EPS guidance to $13.91 - $14.11, reflecting the impact of this expense.
Key Highlights
- Q2 2026 acquired IPR&D and milestones expense expected to be $291 million pre-tax.
- This expense is expected to have an unfavorable impact of $0.17 on Q2 GAAP and non-GAAP diluted EPS.
- Updated Q2 2026 adjusted diluted EPS guidance range is $3.57 - $3.61.
- Updated full-year 2026 adjusted diluted EPS guidance range is $13.91 - $14.11.
- Previous full-year 2026 adjusted diluted EPS guidance was $14.08 - $14.28.
- Previous Q2 2026 adjusted diluted EPS guidance was $3.74 - $3.78.
Price Impact
More from ABBV